GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eupraxia Pharmaceuticals Inc (NAS:EPRX) » Definitions » Short-Term Debt

EPRX (Eupraxia Pharmaceuticals) Short-Term Debt : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Eupraxia Pharmaceuticals Short-Term Debt?

Eupraxia Pharmaceuticals's Short-Term Debt for the quarter that ended in Dec. 2024 was $0.00 Mil.

Eupraxia Pharmaceuticals's quarterly Short-Term Debt declined from Jun. 2024 ($4.55 Mil) to Sep. 2024 ($0.00 Mil) but then stayed the same from Sep. 2024 ($0.00 Mil) to Dec. 2024 ($0.00 Mil).

Eupraxia Pharmaceuticals's annual Short-Term Debt increased from Dec. 2022 ($0.08 Mil) to Dec. 2023 ($10.40 Mil) but then declined from Dec. 2023 ($10.40 Mil) to Dec. 2024 ($0.00 Mil).

Eupraxia Pharmaceuticals Short-Term Debt Historical Data

The historical data trend for Eupraxia Pharmaceuticals's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eupraxia Pharmaceuticals Short-Term Debt Chart

Eupraxia Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Short-Term Debt
Get a 7-Day Free Trial 9.82 0.07 0.08 10.40 -

Eupraxia Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.40 9.52 4.55 - -

Eupraxia Pharmaceuticals Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Eupraxia Pharmaceuticals Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Eupraxia Pharmaceuticals's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Eupraxia Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eupraxia Pharmaceuticals Inc (NAS:EPRX) » Definitions » Short-Term Debt
Comparable Companies
TSXV:NGEN XCNQ:METX TSXV:ARCH TSX:TH TSX:FRX XCNQ:ONCO NEOE:CYBN TSX:MDNA TSX:MSCL TSXV:MIR VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
EPRX:Canada
Address
201-2067 Cadboro Bay Road, Victoria, BC, CAN, V8R 5G4
Website
https://www.eupraxiapharma.com
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs.